Viveve Medical Stock News

Viveve Medical, Inc. (NASDAQ:VIVE) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 300,500 shares, a drop of 26.1% from the November 15th total of 406,400 shares. Approximately 3.0% of the shares of the company are sold short. Based on []

Major milestone achieved in Company''s advance toward a new U.S. SUI indicationENGLEWOOD, CO / ACCESSWIRE / December 14, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focus

Northern Trust Corp acquired a new position in shares of Viveve Medical, Inc. (NASDAQ:VIVE) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 18,168 shares of the companys stock, valued at approximately $54,000. Northern Trust Corp owned 0.17% of Viveve Medical []

Yubo International Biotech (OTCMKTS:YBGJ) and Viveve Medical (NASDAQ:VIVE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings. Risk & Volatility Yubo International Biotech has a beta of 6.22, indicating that its []

Viveve Medical (NASDAQ:VIVE) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends. Valuation & Earnings This table compares Viveve Medical and LivaNovas revenue, earnings per share (EPS) and valuation. []

Zacks Investment Research cut shares of Viveve Medical (NASDAQ:VIVE) from a hold rating to a sell rating in a research report report published on Wednesday morning, Zacks.com reports. According to Zacks, Viveve Medical, Inc. is a medical device company focused on technologies for the cardiac and vascular markets. The Companys lead product, RenalGuard (R), is []

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q3 2021 Results - Earnings Call Transcript

ENGLEWOOD, CO / ACCESSWIRE / November 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its third quart

Biotech penny stocks are heating up right now, here's three to watch The post Are Biotech Penny Stocks Worth Buying? Check These 3 Out appeared first on Penny Stocks to Buy, Picks, News and Informatio

ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q2 2021 Results - Earnings Call Transcript

Total revenue of $1.7M reported for Q2 Reported sales of approximately 3,500 consumable treatment tips - a 42% unit increase quarter-over-quarter Pivotal SUI PURSUIT trial enrollment on-track for comp

The stock price of Viveve Medical Inc (NASDAQ: VIVE) increased by over 3% pre-market. This is why it happened.

ENGLEWOOD, CO / ACCESSWIRE / August 3, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Canadian Intellectual Proper

ENGLEWOOD, CO / ACCESSWIRE / July 6, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive offi